Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabrielle E Bau

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Pediatrics|December 6, 2023
Shifting Trends in Diagnosis of Asthma, Bronchiolitis, and Viral Pneumonia in Young ChildrenMichelle R Brajcich, Gabrielle E Bau, William Tsai, et al.
JAMA Internal Medicine|February 1, 2021
Association of Medical Stimulants With Mortality in the US From 2010 to 2017Joshua C Black, Gabrielle E Bau, Janetta L Iwanicki, et al.
JAMA|March 12, 2026
Psilocybin Trends in States That Decriminalized UseJoshua C Black, Gabrielle E Bau, Ryan R Cook, et al.
Pediatrics|May 5, 2018
Unit-Dose Packaging and Unintentional Buprenorphine-Naloxone ExposuresGeorge Sam Wang, S Geoffrey Severtson, Gabrielle E Bau, et al.
Pharmacoepidemiology and Drug Safety|May 17, 2018
Scoring the best deal: Quantity discounts and street price variation of diverted oxycodone and oxymorphoneJacob A Lebin, David L Murphy, Stevan Geoffrey Severtson, et al.
Journal of the American College of Emergency Physicians Open|October 25, 2024
Buprenorphine, oxycodone, hydrocodone, and methadone mortality in the United States (2010‒2017)Karilynn M Rockhill, Gabrielle E Bau, Angela DeVeaugh-Geiss, et al.
Pain Medicine (Malden, Mass.)|March 17, 2019
Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation StrategyJoshua C Black, Gabrielle E Bau, Travis Rosen, et al.
Clinical Toxicology (Philadelphia, Pa.)|October 10, 2024
Identifying and quantifying exposures involving counterfeit opioid analgesic productsNancy A West, Gabrielle E Bau, Heather Olsen, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Pediatrics|December 6, 2023
Shifting Trends in Diagnosis of Asthma, Bronchiolitis, and Viral Pneumonia in Young ChildrenMichelle R Brajcich, Gabrielle E Bau, William Tsai, et al.
JAMA Internal Medicine|February 1, 2021
Association of Medical Stimulants With Mortality in the US From 2010 to 2017Joshua C Black, Gabrielle E Bau, Janetta L Iwanicki, et al.
JAMA|March 12, 2026
Psilocybin Trends in States That Decriminalized UseJoshua C Black, Gabrielle E Bau, Ryan R Cook, et al.
Pediatrics|May 5, 2018
Unit-Dose Packaging and Unintentional Buprenorphine-Naloxone ExposuresGeorge Sam Wang, S Geoffrey Severtson, Gabrielle E Bau, et al.
Pharmacoepidemiology and Drug Safety|May 17, 2018
Scoring the best deal: Quantity discounts and street price variation of diverted oxycodone and oxymorphoneJacob A Lebin, David L Murphy, Stevan Geoffrey Severtson, et al.
Journal of the American College of Emergency Physicians Open|October 25, 2024
Buprenorphine, oxycodone, hydrocodone, and methadone mortality in the United States (2010‒2017)Karilynn M Rockhill, Gabrielle E Bau, Angela DeVeaugh-Geiss, et al.
Pain Medicine (Malden, Mass.)|March 17, 2019
Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation StrategyJoshua C Black, Gabrielle E Bau, Travis Rosen, et al.
Clinical Toxicology (Philadelphia, Pa.)|October 10, 2024
Identifying and quantifying exposures involving counterfeit opioid analgesic productsNancy A West, Gabrielle E Bau, Heather Olsen, et al.
Pageof 1